CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business UpdateAccesswire • 04/24/24
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSKAccesswire • 04/24/24
CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024Accesswire • 04/18/24
CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer VaccinesAccesswire • 04/16/24
CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSKAccesswire • 04/04/24
Down -14.25% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)Zacks Investment Research • 01/26/24
Down -15.09% in 4 Weeks, Here's Why You Should You Buy the Dip in CureVac N.V. (CVAC)Zacks Investment Research • 01/25/24
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology PlatformAccesswire • 01/05/24
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SEAccesswire • 12/19/23
Can CureVac N.V. (CVAC) Climb 191.74% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 11/21/23
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business UpdateAccesswire • 11/14/23
CureVac Announces Solid Progress in Phase 2 COVID-19 and Seasonal Flu Clinical Development Programs in Collaboration with GSKAccesswire • 11/01/23
CureVac Reports Progress in Intellectual Property Infringement Case Against BioNTech in GermanyAccesswire • 09/28/23
CureVac Advances Seasonal Flu Study to Phase 2 in Collaboration with GSK Following Selection of Promising mRNA Vaccine Candidate with Broad CoverageAccesswire • 09/12/23
CureVac Announces Financial Results for the Second Quarter and First Half of 2023 and Provides Business UpdateAccesswire • 08/17/23
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSKAccesswire • 08/01/23
